EU and US could reach trade deal this weekend - Reuters
On Tuesday, JPMorgan analysts reiterated their Neutral rating and maintained a $68.00 price target on Incyte stock (NASDAQ: NASDAQ:INCY), which currently trades at $67.15. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet, though it’s currently trading at relatively high earnings multiples. The update follows the release of initial data from the first-in-human phase I trial of mCALR (INCA33989) for patients with essential thrombocythemia (ET) who were resistant or intolerant to prior therapies.
The trial data, disclosed earlier today in a late-breaking abstract for the European Hematology Association, included only dose-escalation data for ET patients, with no information on myelofibrosis (MF). The analysts noted that Incyte management had previously indicated that updates on ET and MF might be provided separately. With a market capitalization of nearly $13 billion and a healthy current ratio of 2.04, the company appears well-positioned to continue its research initiatives. The company is awaiting a full dataset, including combination data with Jakafi, suggesting the need for further maturation of the combo cohort.
The early data from the trial showed an encouraging efficacy profile with acceptable tolerability, given the relatively short median exposure of 20 weeks. However, the analysts highlighted that the competitive landscape presents challenges, citing Merck (NSE:PROR)’s bomedemstat (IMG-7289) as a benchmark with ongoing phase III trials.
Looking ahead, Incyte is expected to provide additional details during its investor event on June 15. This may include further follow-up data, specifics on VAF reductions, and insights into responses observed in the trial. The analysts also anticipate updates on when mCALR data for MF might be available, either as a standalone therapy or in combination with Jakafi. For deeper insights into Incyte’s financial health and growth prospects, InvestingPro subscribers can access comprehensive analysis, including 12+ additional ProTips and detailed financial metrics in the Pro Research Report.
In other recent news, Incyte has announced promising trial data for its monoclonal antibody, INCA033989, at the European Hematology Association (EHA) congress in Milan. The data demonstrated safety and efficacy in treating essential thrombocythemia, a type of myeloproliferative neoplasm. Citi analysts reaffirmed their Buy rating for Incyte, citing the promising proof-of-concept data for the mCALR inhibitor, INCA33989. However, BMO Capital maintained an Underperform rating, expressing caution over safety concerns related to the drug and uncertainty about Incyte’s growth strategy beyond its current market leader, Jakafi. UBS analysts also reiterated a Neutral rating, citing concerns over the potential of Incyte’s drug developments, despite recent investor interest. The analysts highlighted uncertainty regarding the progression of the mCALR program to registrational studies. Incyte’s presentations at the EHA congress included data on several other programs within its hematology/oncology portfolio, showcasing the company’s ongoing research efforts. The acceptance of these presentations at a prestigious medical congress suggests confidence in Incyte’s research and development endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.